Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Performanat GmbH is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is under the review of WORSHAM, JESSICA N, who is the busiest examiner for the company with 1 pending action. The company's prosecution profile shows a concentration in 1 distinct art unit and involves only 1 distinct examiner. Because there is only 1 pending office action, the entire current USPTO workload is centralized.
This lack of variety in examiners or art units means that the practitioner's strategy is tied to the specific examination patterns of the 1 distinct examiner assigned to the Biotechnology & Pharmaceuticals technology. The 1 pending office action represents the company's total active engagement with the USPTO, making the 1 distinct examiner's role critical. For the practitioner, this centralized environment requires a focused approach to the 1 distinct art unit's specific requirements. Success in the 1 pending action will depend on navigating the technical standards of the Biotechnology & Pharmaceuticals field as interpreted by WORSHAM, JESSICA N.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WORSHAM, JESSICA N | 1 | 56.6% | +56.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17280381 | CALCIUM COMPOSITION | WORSHAM, JESSICA N | 4d overdue |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17280381 | CALCIUM COMPOSITION | WORSHAM, JESSICA N | 1615 | §103 | Final Rejection | 4d overdue | Pending | Mar 26, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPerformanat GmbH has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jessica N Worsham has the most, with 1 of Performanat GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.